Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.36
+2.7%
$1.23
$0.92
$22.50
$81.29M0.48375,147 shs526,792 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$298.49
-0.6%
$291.28
$200.63
$377.46
$6.64B-1.05359,776 shs108,674 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shsN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$11.19
+1.2%
$10.16
$7.44
$11.82
$557.51M-0.02267,774 shs65,540 shs
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$17.59
$17.67
$9.93
$32.94
$818.60M1.454,965 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
0.00%+25.46%+7.54%+19.91%-78.99%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-0.75%+6.86%-5.06%+9.87%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%-0.31%+1.59%+32.52%+31.43%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.4239 of 5 stars
3.04.00.04.61.93.30.6
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.0879 of 5 stars
3.40.00.04.62.23.30.6
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.0796 of 5 stars
3.30.00.00.02.72.50.6
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50305.90% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.89
Moderate Buy$420.6340.92% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.67
Moderate Buy$16.6048.41% Upside
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TBPH, IGMS, NBRV, MDGL, and ZEAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$24.00 ➝ $25.00
6/17/2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$24.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$441.00 ➝ $458.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$422.00 ➝ $460.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$394.00 ➝ $420.00
4/24/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M30.22N/AN/A$0.82 per share1.65
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$180.13M36.79N/AN/A$34.59 per share8.63
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$64.38M8.69N/AN/A$3.57 per share3.13
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$46.54M17.59N/AN/A$3.38 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$195.79M-$3.270.00N/AN/A-7,417.79%-317.97%-71.43%8/13/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$56.42M-$1.18N/A31.96N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/A

Latest TBPH, IGMS, NBRV, MDGL, and ZEAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
5/1/2025Q1 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.71
5.71
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.17
5.91
5.58
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.77
4.77
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.93
4.79
4.78
CompanyEmployeesShares OutstandingFree FloatOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.70 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million17.43 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
11050.00 million46.55 millionOptionable
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
35546.54 million45.51 millionNot Optionable

Recent News About These Companies

Zealand Pharma Appoints Chief Development Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.36 +0.04 (+2.65%)
Closing price 07/3/2025 03:45 PM Eastern
Extended Trading
$1.34 -0.02 (-1.48%)
As of 07/3/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$298.48 -1.67 (-0.55%)
Closing price 07/3/2025 03:39 PM Eastern
Extended Trading
$298.48 0.00 (0.00%)
As of 07/3/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$11.18 +0.14 (+1.22%)
Closing price 07/3/2025 01:21 PM Eastern
Extended Trading
$11.18 0.00 (0.00%)
As of 07/3/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Zealand Pharma A/S stock logo

Zealand Pharma A/S NASDAQ:ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.